Skip to content

Study · In vitro (cells) · 2019

4 results

The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.

Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, Bai J, Guo X, Zhang Y, Jiang X, Gu J, Xu Y, Geng D

International immunopharmacology20 Jul 2019Cited by 41 (Europe PMC)

PMID31336333 (opens in a new tab)DOI10.1016/j.intimp.2019.105732 (opens in a new tab)PepBankPUB-31336333
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human rheumatoid arthritis synoviocytes, lixisenatide inhibited inflammatory responses through cytokine downregulation, MMP inhibition, and JNK, AP-1 and NF-κB pathway blockade.

    In plain wordsIn cells, lixisenatide inhibited inflammatory responses through changes in cytokines, tissue-degrading enzymes, and signaling pathways.

    Peptide
    Lixisenatide
    Outcome
    DecreaseProinflammatory cytokines, MMPs and signaling
    Study

    humann: not reported in source

    Rheumatoid arthritis fibroblast-like synoviocytes
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    lixisenatide inhibited the inflammatory response through downregulation of proinflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8); inhibition of matrix metalloproteinases (MMPs); and blockade of cellular signaling pathways, including the c-…
    1 context sentence
    Summary · context
    To our knowledge, this is the first study exploring the effects of agonism of the glucagon-like peptide-1 (GLP-1) receptor using lixisenatide, a licensed drug used for the treatment of type II diabetes, on the pathological characteristics of RA in human fibroblast-like synoviocytes.
  2. 02LabIn vitro (cells)Mechanism

    In human rheumatoid arthritis synoviocytes, lixisenatide improved oxidative stress.

    In plain wordsIn cells, lixisenatide improved oxidative stress.

    Peptide
    Lixisenatide
    Outcome
    DecreaseOxidative stress
    Study

    humann: not reported in source

    Rheumatoid arthritis fibroblast-like synoviocytes
    Outcome group
    Oxidative stress · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, lixisenatide improved oxidative stress, rescued mitochondrial membrane potential (ΔΨm), and prevented cell death in fibroblast-like synoviocytes.
    1 context sentence
    Summary · context
    To our knowledge, this is the first study exploring the effects of agonism of the glucagon-like peptide-1 (GLP-1) receptor using lixisenatide, a licensed drug used for the treatment of type II diabetes, on the pathological characteristics of RA in human fibroblast-like synoviocytes.
  3. 03LabIn vitro (cells)Mechanism

    In human rheumatoid arthritis synoviocytes, lixisenatide rescued mitochondrial membrane potential.

    In plain wordsIn cells, lixisenatide restored mitochondrial membrane potential.

    Peptide
    Lixisenatide
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    humann: not reported in source

    Rheumatoid arthritis fibroblast-like synoviocytes
    Outcome group
    Mitochondrial function · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, lixisenatide improved oxidative stress, rescued mitochondrial membrane potential (ΔΨm), and prevented cell death in fibroblast-like synoviocytes.
    1 context sentence
    Summary · context
    To our knowledge, this is the first study exploring the effects of agonism of the glucagon-like peptide-1 (GLP-1) receptor using lixisenatide, a licensed drug used for the treatment of type II diabetes, on the pathological characteristics of RA in human fibroblast-like synoviocytes.
  4. 04LabIn vitro (cells)Mechanism

    In human rheumatoid arthritis synoviocytes, lixisenatide prevented cell death.

    In plain wordsIn cells, lixisenatide prevented cell death.

    Peptide
    Lixisenatide
    Outcome
    DecreaseCell death
    Study

    humann: not reported in source

    Rheumatoid arthritis fibroblast-like synoviocytes
    Outcome group
    Cell viability and death · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, lixisenatide improved oxidative stress, rescued mitochondrial membrane potential (ΔΨm), and prevented cell death in fibroblast-like synoviocytes.
    1 context sentence
    Summary · context
    To our knowledge, this is the first study exploring the effects of agonism of the glucagon-like peptide-1 (GLP-1) receptor using lixisenatide, a licensed drug used for the treatment of type II diabetes, on the pathological characteristics of RA in human fibroblast-like synoviocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.